Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $56.00

Enliven Therapeutics (NASDAQ:ELVN) had its price target lifted by HC Wainwright from $48.00 to $56.00 in a report published on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other analysts have also issued research reports about the stock. Mizuho increased their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.40.

Enliven Therapeutics Stock Down 1.2%

ELVN stock opened at $38.83 on Thursday. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $40.62. The business has a 50-day simple moving average of $28.56 and a 200 day simple moving average of $22.99. The company has a market cap of $2.32 billion, a PE ratio of -20.88 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, COO Anish Patel sold 48,300 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares in the company, valued at $6,018,157.89. This represents a 18.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard A. Heyman sold 9,635 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $25.03, for a total transaction of $241,164.05. Following the completion of the transaction, the director directly owned 25,545 shares of the company’s stock, valued at approximately $639,391.35. The trade was a 27.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 232,180 shares of company stock worth $6,217,033 over the last three months. 25.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Commodore Capital LP lifted its stake in shares of Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after acquiring an additional 17,809 shares during the last quarter. Vestal Point Capital LP grew its position in Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc grew its position in Enliven Therapeutics by 13.5% during the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after acquiring an additional 418,673 shares during the last quarter. Vanguard Group Inc. increased its holdings in Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after purchasing an additional 142,378 shares in the last quarter. Finally, State Street Corp raised its position in Enliven Therapeutics by 9.1% in the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock valued at $16,214,000 after purchasing an additional 87,725 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.